- Home
- PCYO vs CLLS Comparison
PCYO vs CLLS Comparison
Compare PCYO & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PCYO | CLLS |
|---|---|---|
| Founded | 1976 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Water Supply | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 267.7M | 485.6M |
| IPO Year | N/A | 2007 |
Fundamental Metrics
Financial Performance| Metric | PCYO | CLLS |
|---|---|---|
| Price | $11.08 | $4.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 45.7K | ★ 116.7K |
| Earning Date | 11-13-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 12.50 | N/A |
| EPS | ★ 0.54 | N/A |
| Revenue | $26,087,000.00 | ★ $82,551,000.00 |
| Revenue This Year | N/A | $32.58 |
| Revenue Next Year | N/A | $20.68 |
| P/E Ratio | $20.44 | ★ N/A |
| Revenue Growth | N/A | ★ 129.04 |
| 52 Week Low | $9.65 | $1.10 |
| 52 Week High | $12.98 | $5.48 |
Technical Indicators
Market Signals| Indicator | PCYO | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 40.74 | 54.28 |
| Support Level | $11.39 | $4.47 |
| Resistance Level | $11.87 | $5.03 |
| Average True Range (ATR) | 0.36 | 0.28 |
| MACD | -0.10 | -0.02 |
| Stochastic Oscillator | 9.64 | 53.90 |
Price Performance
Historical ComparisonAbout PCYO Pure Cycle Corporation
Pure Cycle Corp is a diversified land and water resource development company. The company designs, constructs, manages, operates, and maintains water and wastewater systems. The firm operates in two business segments namely Water and wastewater resource development and Land development. It generates maximum revenue from the Land development segment. The land resource development segment includes all the activities necessary to develop and sell finished lots.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.